The National Health Service has a new drugs deal
Patients and pharma firms will be relieved. But it is not yet clear who benefits most
TWO DAYS, TWO deals for the National Health Service (NHS). On November 21st the NHS announced that it had awarded a contract worth up to £330m ($414m) to Palantir, a controversial American firm, to help it join up patient data in England and thereby, it hopes, to improve care for millions. This followed the announcement a day earlier of a new drugs deal, after months of wrangling with the British government, which funds the service, and the Association of the British Pharmaceutical Industry (ABPI), representing drugmakers.
Explore more
This article appeared in the Britain section of the print edition under the headline “Drug dealing”
Britain November 25th 2023
- Britain’s chancellor offers tax cuts and fiscal trickery
- Jeremy Hunt wants to improve Britain’s public-sector productivity
- The government tries to unlock growth capital for British firms
- The world’s first pathway for individually designed drugs
- The National Health Service has a new drugs deal
- Is Britain’s plan to send asylum-seekers to Rwanda salvageable?
- Britain’s native farm animals can be rarer than giant pandas
- What kind of legacy does Rishi Sunak want to leave behind?
From the November 25th 2023 edition
Discover stories from this section and more in the list of contents
Explore the editionDiscover more
British MPs vote in favour of assisted dying
A monumental social reform is closer to being realised
The slow death of a Labour buzzword
And what that says about Britain’s place in the world
Britain’s Supreme Court considers what a woman is
At last. Britons had been wondering what those 34m people who are not men might be
Can potholes fuel populism?
A new paper looks at one explanation for the rise of Reform UK
Are British voters as clueless as Labour’s intelligentsia thinks?
How the idea of false consciousness conquered the governing party